Active screening of intestinal carbapenem-resistant Enterobacteriaceae in high-risk patients admitted to the hematology wards and its effect evaluation

• Published in: Zhōnghuá xuèyèxué zázhì Vol. 41; no. 11; p. 932
• Main Authors: Huang, X L, Wu, S H, Shi, P F, Xu, L H, Chen, C, Xie, Y P, Gao, D Q, Chen, K, Tan, J F, Liu, L R, Xu, Y, Yang, F, Yu, M X, Wang, S Y, Qian, S X
• Format: Journal Article
• Language: Chinese
• Published: China 14.11.2020
• Subjects: Anti-Bacterial Agents - therapeutic use; Carbapenem-Resistant Enterobacteriaceae; Cross Infection - epidemiology; Enterobacteriaceae Infections - diagnosis; Enterobacteriaceae Infections - drug therapy; Enterobacteriaceae Infections - epidemiology; Hematology; Humans; Evaluation of effect; Active screening; Carbapenem-resistant Enterobacteriaceae
• ISSN: 0253-2727
• DOI: 10.3760/cma.j.issn.0253-2727.2020.11.009

To evaluate the effect of intestinal carbapenem-resistant Enterobacteriaceae (CRE) active screening combined with enhanced intervention in the prevention and control of nosocomial infection in patients admitted to the hematological ward. Patients who were admitted to the Department of Hematology in a tertiary-care general hospital from March 1, 2017 to December 31, 2019 and underwent chemotherapy or immunosuppressive therapy comprised the intervention group. They were screened for intestinal CRE at least thrice. From December 1, 2016 to February 28, 2017, patients who underwent chemotherapy or immunosuppressive therapy without active intestinal CRE screening in the Department of Hematology formed the control group. Both the patient groups were monitored for CRE infection in real time. The (2) test was used to compare the changes in the CRE infection rate and mortality in high-risk patients before and after the active screening. During the intervention period, the CRE colonization rate of patients was 16.46% (